

Special Issue

Virus-Like Particle and Nano-Particle Vaccines 2.0

Message from the Guest Editors

Nanotechnology is entering an increasing number of branches of science and common life. Nanoparticles of various types have been investigated for a wide variety of applications, including biomedicine. The special properties of virus-like particles have been used in vaccine development. Vaccination has saved many lives and vitally improved global health and life conditions. Nanobiotechnology could increase vaccine development. Nanoparticles, including virus-like particles, have extensive potential as vaccine vehicles, epitope carriers, adjuvants, and other nanobiomedical tools. This Issue will be focused on nanobiotechnology applied in construction or modification of virus-like particles and vaccine development. Therefore, we welcome research articles, short communications, as well as review articles, of a high scientific level on the nanotechnological aspects of molecular virology, vaccinology, and immunology.

Guest Editors

Prof. Dr. Kamil Kuca

Prof. Dr. Jakub D. Rybka

Prof. Dr. Tomasz Pniewski

Deadline for manuscript submissions

closed (28 February 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/63544

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).